🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06718192
Recruiting Phase 1/2

A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts.

NCT06718192 · tracked via the Priya Life Science China tracker
Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Phase 1/2
Started
2024-12-25
Last updated
2025-03-24

Condition(s) studied

Verruca Plantaris

Investigational drug(s) / intervention(s)

Bleomycin injectionCryotherapy

Bleomycin injection: Wart injection (0.2 mL \<5 mm; 0.5 mL 5-10 mm; 1ml for \>10 mm) were injected at a depth of 1.5mm, diluted with normal saline at a concentration of 3u/ml=3mg/ml, and the maximum amount of each wart was 1ml until the wart turned white

Cryotherapy: The wart was frozen by liquid nitrogen until a circle of frozen tissue appeared around the wart for about 10s, with an interval of 30s, for a total of 2 times

Study summary

To evaluate the efficacy of bleomycin and cryopreservation in the treatment of plantar verruca by dermoscopy and explore the influencing factors. Compare the safety, economic burden and impact on quality of life of the two treatments

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: Age 18-65 years old, gender is not limited; Consistent with the diagnosis of plantar warts; Volunteer for treatment and sign informed consent; Consent to photograph the lesion; The treatment target area can be selected (the target area must meet the following conditions: The distance between adjacent warts in the target area is \>0.5cm; The diameter of a single wart in the target area is ≤1.5cm, and/or the diameter of a wart mass is ≤1.5cm; The number of total warts/wart masses in the target area is ≤10). Exclusion Criteria: Patients who can't sign informed consent; Had previously received local treatment for common warts within 1 month; hiv-positive patient; Pregnant and lactating women; Has peripheral vascular disease; Allergic to bleomycin; People who are severely immunocompromised, or who are taking immunosuppressive drugs; Mental illness or cognitive incapacity; Other conditions deemed unsuitable for inclusion, such as inability to cooperate with follow-up, were considered by the researchers.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Fourth Affiliated Hospital Zhejiang University School of Medicine Yiwu Zhejiang Recruiting

More The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06718192 on ClinicalTrials.gov ↗ ← All trials in China